Latest news
Dry AMD patients respond to injection breakthrough studies
Posted: Friday 25 November 2022
Initial findings have shown the majority of people with late-stage dry age-related macular degeneration (AMD) would welcome eye injections as a way of slowing down its progress.
Find out more
Statins and diabetes drugs found to reduce risk of age-related macular degeneration
Posted: Tuesday 8 November 2022
Drugs to control diabetes and lower cholesterol may reduce the risk of developing age-related macular degeneration (AMD), a new study suggests.
Find out more
New partnership to accelerate research into macular disease
Posted: Monday 7 November 2022
Clinical research organisation Ora Inc has partnered with the Macular Society, to accelerate the advancement of new treatments for macular disease and help more patients take part in clinical trials.
Find out more
New research investigates immune system's role in AMD
Posted: Monday 31 October 2022
New research is looking into a specific part of the immune system, called the ‘complement system’, which, when damaged, can lead to age-related macular degeneration (AMD).
Find out more
Experts unite to find a cure for dry AMD
Posted: Friday 21 October 2022
Global experts in macular disease will meet in the US this month to speed up the progress being made to find a cure for dry age-related macular degeneration (AMD).
Find out more
Participants needed for Charles Bonnet research
Posted: Saturday 1 October 2022
Scientists want to understand more about how visual hallucinations caused by sight loss impact the daily lives of those affected.
Find out more
Drug shows potential to slow down dry AMD progression
Posted: Thursday 29 September 2022
A new drug being trialled in patients with dry age-related macular degeneration (AMD) has been shown to reduce the rate of progression of the disease in its late stages.
Find out more
Gene therapy trial tests injection lasting three years
Posted: Friday 23 September 2022
A new clinical trial is underway to test a gene therapy which could treat wet age-related macular degeneration (AMD), with an eye injection lasting up to three years.
Find out more
Faricimab - all you need to know about the new treatment for wet AMD and DMO
Posted: Tuesday 30 August 2022
"There's a long way to go but I'm more optimistic. I was thinking of retiring a few years ago, now I'm so excited about the treatments we can offer patients I'll probably stay another few years."
Find out more
Thousands of patients with diabetes-related sight loss given access to new treatment
Posted: Thursday 11 August 2022
Thousands of patients with diabetic macular oedema (DMO) could benefit from a steroid treatment, which has previously only been available to those who have received cataract surgery.
Find out more
"It could be life-changing for so many people"
Posted: Wednesday 3 August 2022
A 75-year-old man involved in a clinical trial for a new implant for wet age-related macular degeneration (AMD) says it would be ‘magic’ if the trial is successful.
Find out more
Ophthalmologist to reveal more about new drug for two types of macular disease
Posted: Wednesday 3 August 2022
An ophthalmologist who has worked on the clinical trials for the latest drug approved to treat wet age-related macular degeneration (AMD) and diabetic macular oedema (DMO) will reveal more about the treatment and how you can access it, as part of the Macular Society’s monthly webinar series.
Find out more
Get the latest news and advice from the Macular Society
To hear about life-changing research, treatments and tips for living with sight loss, subscribe to our monthly enewsletter today. Together we can Beat Macular Disease.
Sign up to our free email newsletter
